The WHO interim recommendations on
the use of the Janssen Ad26.COV2.S (COVID-19) vaccine were developed using
advice from the Strategic Advisory Group of Experts on Immunization (SAGE) and
the evidence summary included in the background document linked below.
Version 15 June 2021 of this
document has been released.
The SAGE recommendation for the
use of Janssen Ad26.CoV2.S is a single intramuscular dosage of 0.5 mL with a
minimum of 14 days between the J&J vaccination and any other vaccines that
the recipient may need to protect against other health concerns. However, if
more information on co-administration with other vaccines becomes available,
this recommendation may be revised.
The SAGE recommendation for the
use of Janssen Ad26.CoV2.S is a single intramuscular dosage of 0.5 mL with a
minimum of 14 days between the J&J vaccination and any other vaccines that
the recipient may need to protect against other health concerns. However, if
more information on co-administration with other vaccines becomes available,
this recommendation may be revised.
SAGE, which oversees and makes
recommendations on pharmaceuticals and vaccines for WHO has thoroughly
examined the data on the vaccine's quality, safety, and efficacy before
recommending it for people aged 18 and over. The European Medicines Agency
(EMA) and the United States Food and Drug Administration (FDA) have both found
that SAGE's suggestion is safe for you.
The J&J Janssen Ad26.CoV2.S
has been found to be effective against other SARS-CoV-2 virus variants,
including the B1.351, which was first identified in South Africa, and the P2,
which was first identified in Brazil, with efficacy levels as high as 85.4
percent against severe disease and hospitalization and 66.9% against
symptomatic moderate and severe SARS-CoV-2 infection.
There is currently no substantive
data available in determining the impact of Ad26.COV2.S on virus transmission
that causes COVID-19 disease; as a result, it is recommended that we continue
to practice and strengthen public health measures that work, such as the use of
face masks, physical separation, hand washing, respiratory and cough hygiene,
avoiding crowds, and proper ventilation.
Vaccination session and vaccine
administration: All people should continue to follow the current COVID-19
protection guidelines in their area before, during, and after vaccination (e.g.
wearing a mask, keeping physical distance, hand hygiene).
A person who has signs of COVID-19
should not be immunized. People who have recovered from symptomatic or
asymptomatic COVID-19 may be offered vaccination.
Although testing is not advised
for vaccine decision-making, patients with PCR-confirmed SARS-CoV-2 infection
in the preceding 6 months may choose to delay vaccination until towards the end
of this period based on existing data.
As of April 19, 2021, the Janssen
vaccine was considered safe and effective at protecting people from the highly
dangerous dangers of COVID-19, including death, hospitalization, and severe
disease, under WHO surveillance and in close collaboration with EMA, FDA, and
other regulators throughout the world.
Nonetheless, Johnson &
Johnson, realizing the importance of ongoing research into ways to make
vaccines as effective as possible against all types of pandemics and infectious
diseases continue to work tirelessly to improve on what they have already
done, mobilizing its deep scientific expertise and large international and
global workforce to keep to their commitment to addressing the health needs of
people, communities, and healthcare officers around the world.
Hopefully, with its contribution
to the fight against the Covid-19 pandemic, the world will be able to return to
life as we used to know and love it without fear of being consumed by a
pandemic sooner rather than later.
We make every attempt to offer you high-quality content that is relevant to you. More information on the
Johnson and Johnson Covid-19 Vaccine is available at The Watchtower, an
award-winning web design, and development agency based in London and Dubai. On the website, you'll also find aspiring content on movies, cinemas, lifestyle, content,
and firm marketing, and production.
© Copyright The Watchtower 2010 - .
Comments (0)
Write a Comment